Scott Guenthner

941 total citations
22 papers, 317 citations indexed

About

Scott Guenthner is a scholar working on Dermatology, Epidemiology and Immunology. According to data from OpenAlex, Scott Guenthner has authored 22 papers receiving a total of 317 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Dermatology, 7 papers in Epidemiology and 6 papers in Immunology. Recurrent topics in Scott Guenthner's work include Psoriasis: Treatment and Pathogenesis (6 papers), Skin and Cellular Biology Research (4 papers) and Dermatology and Skin Diseases (4 papers). Scott Guenthner is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (6 papers), Skin and Cellular Biology Research (4 papers) and Dermatology and Skin Diseases (4 papers). Scott Guenthner collaborates with scholars based in United States, Canada and Australia. Scott Guenthner's co-authors include Robert Hurwitz, Howard R. Gray, Mark Lebwohl, Kim Papp, David S. Rubenstein, Bruce Strober, Hwanhee Hong, Linda Stein Gold, Anna M. Tallman and Robert Bissonnette and has published in prestigious journals such as New England Journal of Medicine, PLoS ONE and Journal of the American Academy of Dermatology.

In The Last Decade

Scott Guenthner

20 papers receiving 312 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Scott Guenthner United States	8	202	161	75	47	40	22	317
Ivan Grozdev Bulgaria	12	196 1.0×	292 1.8×	40 0.5×	29 0.6×	56 1.4×	19	480
Huiqun Ma China	8	159 0.8×	250 1.6×	38 0.5×	44 0.9×	71 1.8×	14	389
Franco Melchi Italy	8	207 1.0×	173 1.1×	40 0.5×	134 2.9×	66 1.6×	9	429
Eleonora Cinelli Italy	15	328 1.6×	363 2.3×	54 0.7×	48 1.0×	40 1.0×	36	540
Giovanna Malara Italy	12	159 0.8×	231 1.4×	72 1.0×	43 0.9×	18 0.5×	26	347
André Vicente Esteves de Carvalho Brazil	12	133 0.7×	222 1.4×	33 0.4×	35 0.7×	32 0.8×	34	319
Bruno de Oliveira Rocha Brazil	8	144 0.7×	294 1.8×	29 0.4×	27 0.6×	55 1.4×	16	428
Klaudia Dopytalska Poland	9	154 0.8×	230 1.4×	39 0.5×	40 0.9×	52 1.3×	16	355
C. Karimkhani Aksut United States	4	130 0.6×	177 1.1×	17 0.2×	36 0.8×	28 0.7×	4	270
Jennifer Frueh Switzerland	8	134 0.7×	298 1.9×	31 0.4×	19 0.4×	41 1.0×	14	369

Countries citing papers authored by Scott Guenthner

Since Specialization

Citations

This map shows the geographic impact of Scott Guenthner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott Guenthner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott Guenthner more than expected).

Fields of papers citing papers by Scott Guenthner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott Guenthner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott Guenthner. The network helps show where Scott Guenthner may publish in the future.

Co-authorship network of co-authors of Scott Guenthner

This figure shows the co-authorship network connecting the top 25 collaborators of Scott Guenthner. A scholar is included among the top collaborators of Scott Guenthner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott Guenthner. Scott Guenthner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Marathe, Kalyani, Joyce Teng, Scott Guenthner, et al.. (2023). Topical Isotretinoin (TMB-001) Treatment for 12 Weeks Did Not Result in Clinically Relevant Laboratory Abnormalities in Participants with Congenital Ichthyosis in the Phase 2b CONTROL Study. Dermatology and Therapy. 13(6). 1255–1264. 2 indexed citations

Blauvelt, Andrew, Javier Alonso‐Llamazares, Neal Bhatia, et al.. (2023). Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial. SKIN The Journal of Cutaneous Medicine. 7(2). s196–s196.

Murrell, Dédée F., Joyce Teng, Scott Guenthner, et al.. (2023). Phase IIb randomized CONTROL study demonstrates a novel topical isotretinoin formulation, TMB-001, is safe and effective in participants with either recessive X-linked or autosomal recessive lamellar congenital ichthyosis. Clinical and Experimental Dermatology. 48(6). 623–630. 5 indexed citations

Bunick, Christopher G., Joyce Teng, Scott Guenthner, et al.. (2023). Characteristics and outcomes for participants with congenital ichthyosis who responded to treatment with the topical isotretinoin formulation TMB-001: results from the Phase IIb CONTROL study. Clinical and Experimental Dermatology. 48(7). 765–769. 1 indexed citations

Sofen, Howard, et al.. (2023). Efficacy of Tapinarof Cream 1% Once Daily for the Treatment of Mild to Severe Intertriginous Plaque Psoriasis. SKIN The Journal of Cutaneous Medicine. 7(6). s235–s235. 1 indexed citations

Sekulić, Aleksandar, Simon Yoo, Ragini R. Kudchadkar, et al.. (2022). Real-world assessment and treatment of locally advanced basal cell carcinoma: Findings from the RegiSONIC disease registry. PLoS ONE. 17(1). e0262151–e0262151. 11 indexed citations

Teng, Joyce, Christopher G. Bunick, Scott Guenthner, et al.. (2022). The CONTROL study: A randomized, double-blind vehicle-controlled phase 2b study of novel topical isotretinoin formulation demonstrates improvement in recessive X-linked and autosomal recessive lamellar congenital ichthyosis. Journal of the American Academy of Dermatology. 87(6). 1455–1458. 7 indexed citations

Lebwohl, Mark, et al.. (2022). 31865 Pooled efficacy and safety results from the DERMIS-1 and DERMIS-2 phase 3 trials of once-daily roflumilast cream 0.3% for treatment of chronic plaque psoriasis. Journal of the American Academy of Dermatology. 87(3). AB93–AB93. 1 indexed citations

Rosso, J.Q. Del, Scott Guenthner, Chih-ho Hong, et al.. (2022). Exposure–Response Analysis Demonstrates Response to Tapinarof is Driven by Local Effects at Sites of Application. SKIN The Journal of Cutaneous Medicine. 6(6). s50–s50. 1 indexed citations

10.

Guenthner, Scott, Jayson Rieger, David K. Glover, et al.. (2021). Phase II, Double-Blind, Vehicle-Controlled Study to Determine the Cantharidin Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts. American Journal of Clinical Dermatology. 22(6). 867–875. 1 indexed citations

11.

Guenthner, Scott, Pearl Kwong, Jayson Rieger, et al.. (2021). COVE-1: A Phase 2, Open-Label Study to Evaluate Efficacy and Safety and the Optimal Regimen of VP-102, a Proprietary Drug–Device Product Containing Topical Cantharidin (0.7% w/v) Under Occlusion for the Treatment of Common Warts. Dermatology and Therapy. 11(5). 1623–1634. 1 indexed citations

12.

Lebwohl, Mark, Linda Stein Gold, Bruce Strober, et al.. (2021). Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis. New England Journal of Medicine. 385(24). 2219–2229. 125 indexed citations

13.

Travers, Jeffrey B., J. Mikhail Kellawan, Scott Guenthner, et al.. (2020). Inter- and Intra-Physician Variation in Quantifying Actinic Keratosis Skin Photodamage. PubMed. 8(2). 1–4. 1 indexed citations

14.

Lebwohl, Mark, Linda Stein Gold, Bruce Strober, et al.. (2020). Tapinarof Cream 1% QD for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials. SKIN The Journal of Cutaneous Medicine. 4(6). s75–s75. 7 indexed citations

15.

Cook-Bolden, Fran, et al.. (2020). Halobetasol Propionate Lotion 0.01% for Moderate-to-Severe Plaque Psoriasis: Pooled Analysis in Male and Female Participants. Journal of Drugs in Dermatology. 19(8). 747–754. 1 indexed citations

16.

Gooderham, Melinda, Leon Kircik, Matthew Zirwas, et al.. (2020). The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Atopic Dermatitis: Phase 2 Proof-of-Concept Study. SKIN The Journal of Cutaneous Medicine. 4(6). s93–s93. 4 indexed citations

17.

Lebwohl, Mark, Andrew Blauvelt, Alan Menter, et al.. (2019). Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study. American Journal of Clinical Dermatology. 20(6). 863–871. 30 indexed citations

18.

Schaefer, Caroline, Joseph C. Cappelleri, Jason C. Cole, et al.. (2015). Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States. Journal of the American Academy of Dermatology. 73(4). 585–593.e3. 43 indexed citations

19.

Guenthner, Scott, et al.. (2003). A skin cancer education initiative at a professional baseball game and results of a skin cancer survey. International Journal of Dermatology. 42(7). 524–529. 10 indexed citations

20.

Guenthner, Scott, et al.. (1999). Cutaneous squamous cell carcinomas consistently show histologic evidence of in situ changes: A clinicopathologic correlation. Journal of the American Academy of Dermatology. 41(3). 443–448. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact